Sumitra Ananda

2.6k total citations
54 papers, 468 citations indexed

About

Sumitra Ananda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sumitra Ananda has authored 54 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in Sumitra Ananda's work include Colorectal Cancer Treatments and Studies (22 papers), Pancreatic and Hepatic Oncology Research (13 papers) and Cancer Genomics and Diagnostics (13 papers). Sumitra Ananda is often cited by papers focused on Colorectal Cancer Treatments and Studies (22 papers), Pancreatic and Hepatic Oncology Research (13 papers) and Cancer Genomics and Diagnostics (13 papers). Sumitra Ananda collaborates with scholars based in Australia, United States and New Zealand. Sumitra Ananda's co-authors include Chris Brown, Lawrence Cher, Anna K. Nowak, Anthony Dowling, Mark Rosenthal, John Simes, Peter Gibbs, Anne Hamilton, Maira Kentwell and Yoland Antill and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Sumitra Ananda

50 papers receiving 466 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sumitra Ananda Australia 12 224 133 89 85 84 54 468
D. Mirchandani United States 7 165 0.7× 101 0.8× 88 1.0× 127 1.5× 78 0.9× 15 379
Uwe-Jochen Göhring Germany 13 199 0.9× 163 1.2× 74 0.8× 105 1.2× 35 0.4× 35 531
Diana P. English United States 14 275 1.2× 183 1.4× 85 1.0× 112 1.3× 28 0.3× 31 676
Aliki Taylor United Kingdom 11 385 1.7× 133 1.0× 112 1.3× 87 1.0× 30 0.4× 17 613
Inge Ubink Netherlands 14 241 1.1× 145 1.1× 97 1.1× 86 1.0× 21 0.3× 19 459
Audrey Mailliez France 15 502 2.2× 180 1.4× 109 1.2× 351 4.1× 93 1.1× 74 776
Ana Santaballa Spain 17 337 1.5× 180 1.4× 197 2.2× 138 1.6× 51 0.6× 87 753
Erika Matos Slovenia 8 210 0.9× 105 0.8× 199 2.2× 75 0.9× 33 0.4× 27 409
Albert J. Bonebrake United States 14 245 1.1× 106 0.8× 49 0.6× 98 1.2× 36 0.4× 23 531
Samuel G.W. Ow Singapore 12 255 1.1× 99 0.7× 128 1.4× 66 0.8× 38 0.5× 50 426

Countries citing papers authored by Sumitra Ananda

Since Specialization
Citations

This map shows the geographic impact of Sumitra Ananda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumitra Ananda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumitra Ananda more than expected).

Fields of papers citing papers by Sumitra Ananda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumitra Ananda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumitra Ananda. The network helps show where Sumitra Ananda may publish in the future.

Co-authorship network of co-authors of Sumitra Ananda

This figure shows the co-authorship network connecting the top 25 collaborators of Sumitra Ananda. A scholar is included among the top collaborators of Sumitra Ananda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumitra Ananda. Sumitra Ananda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burns, Christopher J., Terrie‐Anne Cock, Anthony C. Bishop, et al.. (2024). Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis.. Journal of Clinical Oncology. 42(16_suppl). e16337–e16337. 1 indexed citations
2.
3.
Bressel, Mathias, Yi-An Ko, Anne Hamilton, et al.. (2024). Beacon: A phase II study of bevacizumab, atezolizumab, and cobimetinib in patients with recurrent, platinum resistant, high grade serous ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 5565–5565. 1 indexed citations
4.
Lee, Belinda, Daniel Croagh, Marion Harris, et al.. (2024). Mutated KRASas a promising target in pancreas cancer: PURPLE registry data to inform real-world incidence and prognostic significance and to aid trial recruitment.. Journal of Clinical Oncology. 42(16_suppl). 11150–11150. 1 indexed citations
5.
Mendis, Shehara, Lara Lipton, Sumitra Ananda, et al.. (2024). Early onset pancreatic cancer—exploring contemporary treatment and outcomes using real-world data. British Journal of Cancer. 130(9). 1477–1484. 4 indexed citations
6.
Tie, Jeanne, Yuxuan Wang, Serigne Lo, et al.. (2024). Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.. Journal of Clinical Oncology. 42(16_suppl). 108–108. 11 indexed citations
7.
8.
Ananda, Sumitra, Yuxuan Wang, Wei Hong, et al.. (2023). Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC).. Journal of Clinical Oncology. 41(16_suppl). 5553–5553. 2 indexed citations
9.
10.
Deftereos, Irene, Nicole Kiss, Teresa Brown, et al.. (2021). Awareness and perceptions of nutrition support in upper gastrointestinal cancer surgery: A national survey of multidisciplinary clinicians. Clinical Nutrition ESPEN. 46. 343–349. 9 indexed citations
11.
Wong, Vanessa, Jeremy Shapiro, Rachel Wong, et al.. (2021). Treatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases. Clinical Colorectal Cancer. 20(4). e233–e239. 4 indexed citations
12.
Wong, Vanessa, Jeremy Shapiro, Rachel Wong, et al.. (2021). Outcomes of isolated distant lymph node metastases in colorectal cancer.. Journal of Clinical Oncology. 39(3_suppl). 84–84. 1 indexed citations
13.
Lee, Belinda, Shehara Mendis, Benjamin Thomson, et al.. (2021). Investigating real-world treatment sequencing outcomes in advanced pancreatic cancer: A purple translational registry analysis.. Journal of Clinical Oncology. 39(3_suppl). 386–386. 1 indexed citations
14.
Cascinu, Stefano, G. Bodoky, Kei Muro, et al.. (2020). Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. The Oncologist. 26(3). e414–e424. 4 indexed citations
15.
Begbie, Stephen, Suzanne Kosmider, Sumitra Ananda, et al.. (2020). Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. Clinical Colorectal Cancer. 20(1). e21–e34. 7 indexed citations
16.
Kentwell, Maira, Yoland Antill, C. David Wrede, et al.. (2017). Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecologic Oncology. 145(1). 130–136. 80 indexed citations
17.
Khasraw, Mustafa, Sumitra Ananda, & Michael Michael. (2016). Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy. 16(4). 391–401. 1 indexed citations
18.
Vergote, Ignace, Russell J. Schilder, Charles H. Pippitt, et al.. (2014). A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecologic Oncology. 135(1). 25–33. 15 indexed citations
19.
Khasraw, Mustafa, et al.. (2013). Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy. 13(4). 451–459. 4 indexed citations
20.
Wong, Shirley, Sumitra Ananda, Ignace Vergote, et al.. (2012). A PHASE 1B STUDY OF TREBANANIB (AMG 386) IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) OR TOPOTECAN (T) IN WOMEN WITH RECURRENT OVARIAN CANCER. Asia-Pacific Journal of Clinical Oncology. 8. 316–317. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Mirchandani Breakdown of academic impact, for papers by Uwe-Jochen Göhring Breakdown of academic impact, for papers by Diana P. English Breakdown of academic impact, for papers by Aliki Taylor Breakdown of academic impact, for papers by Inge Ubink Breakdown of academic impact, for papers by Audrey Mailliez Breakdown of academic impact, for papers by Ana Santaballa Breakdown of academic impact, for papers by Erika Matos Breakdown of academic impact, for papers by Albert J. Bonebrake Breakdown of academic impact, for papers by Samuel G.W. Ow
Rankless by CCL
2026